For free samples, call 1-866-318-6977

For free samples, call 1-866-318-6977


Annual out-of-pocket maximum for prescription

The most a patient has to pay for prescription medications in a plan year. After a patient spends this amount on deductibles, co-payments, and co-insurance, their insurance plan pays 100% of the costs of prescription medications. The out-of-pocket limit doesn't include monthly premiums or anything spent on prescription medications that their plan doesn't cover.


An appeal is a way for offices and patients to request insurers to reconsider their decision to reject a claim. An appeal is typically conducted following a prior authorization denial. Appeals are filed using a process specific to each health plan; therefore, you should inquire about the specific process for a given insurer.

Appeals process

You use the appeals process to formally disagree with any insurer decision about a patient's healthcare services. It requires the insurer to review its initial decision again. Insurers must tell patients in writing how to appeal. Patients' appeals rights and the appeals process are covered in plan documents and on the back of each explanation of benefits (EOB) form.


Co-insurance is the percentage of healthcare costs the patient pays after meeting their deductible, but before reaching their out-of-pocket maximum. For example, an insurer might pay 75% and the patient would pay 25%.

Commercial health insurance

Commercial health insurance is any type of health insurance policy not offered or provided by the government. Providers are generally for profit and offer group and individual plans. The majority of Americans receive their insurance through an employer that covers all or part of the premium, with the remaining cost deducted from the employee's payroll.

Co-pay accumulator program

An approach that some health plans take that does not count the cost of a prescription drug to be applied to the annual deductible if a co-pay card or co-pay reimbursement is used.


A co-payment, or co-pay, is a predictable, pre-set, flat amount a patient pays when they receive a covered service—like doctor visits, prescription drugs, and other healthcare services.


A deductible is the dollar amount patients must pay themselves before their insurer starts contributing to the cost of medications and other services. After they meet the deductible, patients pay a co-payment for covered services and the insurance company pays the rest. Some plans have separate deductibles for prescription drugs and other specific services.


A formulary is a list of prescription drugs covered by an insurer. If a specific drug isn't listed on the formulary, the insurer may deny coverage and require the use of an alternative drug. Formularies organize prescription drugs into categories, or tiers, based on the co-payment the patient is responsible for paying— for example, a patient may pay $5, $10, $20 or more depending on the drug. Generic drugs have the lowest co-payments—sometimes even $0. Brand-name and specialty drugs can have much higher co-payments or percentage-based prices associated with the cost of the drug.


The Health Insurance Portability and Accountability Act of 1996 (HIPAA) is a federal law that required the creation of national standards to protect sensitive patient health information from being disclosed without the patient's consent or knowledge. The US Department of Health and Human Services issued the HIPAA Privacy Rule to implement the requirements of HIPAA. The HIPAA Security Rule protects a subset of information covered by the Privacy Rule.

In-network providers

The providers that a patient's plan has contracted with to provide healthcare services.

Medical exception

A medical exception is a request asking an insurer to waive its rules for a patient's particular circumstance. Common exceptions that may be requested include drug limits, coverage for nonformulary drugs, and tier pricing. To be approved for coverage, a request for an exception must include information from the prescriber about the medical necessity of the change.

Out-of-network providers

Providers who do not contract with a patient's health insurance or plan. Out-of-network co-insurance and co-payments are usually more than those in-network.

PA—prior authorization or prior approval

Some insurers require patients to receive authorization or approval before they'll cover a particular prescription. The reasons vary and can include the medication itself, the quantity prescribed, or the frequency of its administration. If the plan doesn't grant approval, it may not provide coverage. Prior authorizations may take up to 72 hours to process.

Pharmacy benefit

The prescription medications covered under an insurance plan.


The amount people pay for health insurance every month. In addition to premiums, people pay other costs for their healthcare, including a deductible, co-payments, and co-insurance.

Prescription deductible

The amount a patient pays for drugs before their health plan starts to pay a portion of the costs.

Prescription drug coverage

Health insurance (or plan) that helps pay for prescription drugs and medications.

Step therapy

In some cases, patients are required to first try certain drugs to treat their medical condition before the insurer will cover another drug for that condition. The prescriber and plan work together to ensure coverage.


Most formularies are divided into different categories, called tiers, with increasingly higher co-payments. A typical 5-tier formulary organizes prescription drugs into preferred generic, preferred brand name, nonpreferred generic or brand name, specialty, and all others.

10/21 150578

Expand ISI




COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.



Collapse ISI


COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis (AS).

COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.

COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS).



COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX.



COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. In placebo-controlled clinical trials in subjects with moderate to severe PsO, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed in subjects treated with COSENTYX compared to placebo-treated subjects. A similar increase in risk of infection in subjects treated with COSENTYX was seen in placebo‑controlled trials in subjects with PsA, AS and nr-axSpA. The incidence of some types of infections, including fungal infections, appeared to be dose‑dependent in clinical trials.

In the postmarketing setting, serious and some fatal infections have been reported in patients treated with COSENTYX.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.

Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Avoid administration of COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients closely for signs and symptoms of active TB during and after treatment.

Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) exacerbations, in some cases serious and/or leading to discontinuation of COSENTYX, occurred in COSENTYX treated subjects during clinical trials in PsO, PsA, AS, nr-axSpA, and HS. In adult subjects with HS, the incidence of IBD was higher in subjects who received COSENTYX 300 mg every 2 weeks (Ulcerative Colitis [UC] 1 case, EAIR 0.2/100 subject-years; Crohn's Disease [CD] 1 case, EAIR 0.2/100 subject-years) compared to subjects who received COSENTYX 300 mg every 4 weeks (IBD 1 case, EAIR 0.2/100 subject-years). In addition, new onset IBD cases occurred in subjects treated with COSENTYX in clinical trials. In an exploratory trial in 59 subjects with active Crohn’s disease [COSENTYX is not approved for the treatment of Crohn's disease], there were trends toward greater disease activity and increased adverse reactions in subjects treated with COSENTYX as compared to placebo-treated subjects.

Exercise caution when prescribing COSENTYX to patients with IBD. Patients treated with COSENTYX should be monitored for signs and symptoms of IBD.

Eczematous Eruptions

In postmarketing reports, cases of severe eczematous eruptions, including atopic dermatitis‑like eruptions, dyshidrotic eczema, and erythroderma, were reported in patients receiving COSENTYX; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of COSENTYX.

Treatment may need to be discontinued to resolve the eczematous eruption. Some patients were successfully treated for eczematous eruptions while continuing COSENTYX.

Hypersensitivity Reactions

Anaphylaxis and cases of urticaria occurred in COSENTYX treated subjects in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable caps of the COSENTYX Sensoready® pen and the COSENTYX 1 mL and 0.5 mL prefilled syringes contain natural rubber latex, which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.


Prior to initiating therapy with COSENTYX, consider completion of all age-appropriate immunizations according to current immunization guidelines. COSENTYX may alter a patient’s immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.


Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Please see full Prescribing Information, including Medication Guide.